Litfulo Capsules Special Investigation
NCT06279221 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 487
Last updated 2026-03-02
Summary
The objective of this Study is to confirm the safety during the long-term use of this drug and the effectiveness during the use of this drug under the actual use in the patients treated with this drug.
Conditions
Interventions
- DRUG
-
LITFULO
as provided in real world practice
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 0 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-03-01
- Primary Completion
- 2030-04-24
- Completion
- 2030-04-24
Countries
- Japan
Study Locations
More Related Trials
-
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
NCT07029828 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age
NCT05650333 ·Status: COMPLETED ·Phase: PHASE1
-
Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)
NCT05522556 ·Status: AVAILABLE
-
PF-06651600 for the Treatment of Alopecia Areata
NCT03732807 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata
NCT07023302 ·Status: RECRUITING ·Phase: PHASE3
-
Treatment of Alopecic Scars by Follicular Unit Extraction Hair Transplantation
NCT06145672 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT06531109 ·Status: RECRUITING
-
Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study
NCT06202560 ·Status: COMPLETED ·Phase: NA
-
Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata
NCT03800979 ·Status: COMPLETED ·Phase: PHASE4
-
Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia
NCT04409041 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth
NCT02793557 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Novel Formulation of Sildenafil-loaded Nanocarriers for Treatment of Alopecia Areata
NCT06527729 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Hair Up Prospective Study
NCT03652701 ·Status: WITHDRAWN ·Phase: NA
-
Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
NCT02812342 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
NCT03315689 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
NCT05556265 ·Status: TERMINATED ·Phase: PHASE2
-
Ritlecitinib for Cicatricial Alopecia
NCT05549934 ·Status: COMPLETED ·Phase: PHASE2
-
Tofacitinib for the Treatment of Alopecia Areata and Its Variants
NCT02312882 ·Status: COMPLETED ·Phase: NA
-
Pharmacogenomic Study of Androgenetic Alopecia
NCT01227031 ·Status: UNKNOWN
-
Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
NCT05051761 ·Status: COMPLETED ·Phase: PHASE3
-
Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US
NCT07226531 ·Status: ACTIVE_NOT_RECRUITING
-
ENERGI-F701 for Female Hair Loss Treatment
NCT03351322 ·Status: COMPLETED ·Phase: PHASE2
-
Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis
NCT02299297 ·Status: COMPLETED ·Phase: PHASE2
-
Dupilumab in the Treatment of Pediatric Alopecia Areata
NCT05866562 ·Status: RECRUITING ·Phase: PHASE2